Quanterix 과거 순이익 실적
과거 기준 점검 0/6
Quanterix 의 수입은 연평균 -8.6%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 3.8%의 비율로 감소했습니다. 매출은 연평균 6.6%의 비율로 증가해 왔습니다.
핵심 정보
-8.56%
순이익 성장률
-4.03%
주당순이익(EPS) 성장률
| Life Sciences 산업 성장률 | 21.51% |
| 매출 성장률 | 6.56% |
| 자기자본이익률 | -36.93% |
| 순이익률 | -71.86% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 01
QTRX: Alzheimer’s Blood Test Progress Will Support Long Term Upside Potential
Analysts have reduced their price target on Quanterix by $2, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E that were reflected in recent Street research, including a $4 reduction highlighted by Canaccord. Analyst Commentary Recent research around the target cut focuses less on a single headline number and more on how updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E compare with execution risk.
내러티브 업데이트 • Apr 16
QTRX: Expanding Alzheimer’s Blood Screening Access Will Support Stronger Future Earnings Power
Narrative Update on Quanterix The latest analyst price target on Quanterix has been revised in line with updated assumptions for discount rate, revenue growth, profit margin, and future P/E, as analysts adjust their models to reflect a slightly different balance of growth expectations and risk. What's in the News Lucent Diagnostics partnered with Life Line Screening to offer a non-invasive blood based biomarker test for Alzheimer's disease nationally, with programs already underway in Florida, California, and Texas, using a mobile model that reaches community centers, churches, and senior centers (Client Announcements).Seeking Alpha • Apr 10
Quanterix: No Green Shoots
Summary Quanterix Corporation shares have halved in 2025, reflecting persistent losses and underwhelming sales momentum despite a substantial net cash position. Quanterix's 2026 guidance signals flat revenues ($169–$174M) and gross margins in line with 2025, with cash flow break-even targeted in the year's second half. Cost synergies from the Akoya deal are largely realized, but QTRX operating losses remain significant, and sequential revenue or margin gains are lacking. QTRX stock's valuation is historically cheap at 0.3x sales, yet repeated disappointments and missed promises keep investor sentiment extremely cautious. Read the full article on Seeking Alpha내러티브 업데이트 • Apr 02
QTRX: Alzheimer’s Blood Test Advancements Will Drive Strong Long Term Upside
Analysts made a modest adjustment to their price target on Quanterix, trimming it by $0.10 to reflect slightly lower assumptions for revenue growth and profit margins, along with a somewhat higher expected future P/E and discount rate. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte, algorithmic blood test intended to aid in evaluating patients with cognitive symptoms for possible Alzheimer’s disease.내러티브 업데이트 • Mar 19
QTRX: Alzheimer’s Blood Test Progress Will Support Stronger Earnings Power Ahead
Analysts have nudged their price target on Quanterix to $8.00 from $8.00, reflecting slightly updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, without a clear shift in overall valuation stance. What's in the News Quanterix issued earnings guidance for 2026, with expected revenues between US$169 million and US$174 million, providing a concrete management view of the top line for that year (Corporate guidance).내러티브 업데이트 • Mar 04
QTRX: Alzheimer’s Blood Test Progress Will Shape Favorable Long Term Outlook
Analysts have made modest adjustments to their price targets on Quanterix, reflecting updated views on discount rates, revenue growth expectations, profit margins, and future P/E assumptions, while keeping their overall fair value estimate broadly in line with prior levels. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer's disease, supported by clinical evidence in over 1,800 symptomatic patients across three cohorts.
내러티브 업데이트 • Feb 18
QTRX: Alzheimer’s Blood Test Progress Will Drive Long-Term Upside Potential
Analysts have lifted their price target on Quanterix to $7.00 from $7.00, reflecting slight tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that leave their overall valuation view essentially unchanged. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. FDA for a multi analyte algorithmic blood test for Alzheimer's disease, aiming to support evaluation of patients with cognitive symptoms using a non invasive, high performance diagnostic tool (Key Developments).내러티브 업데이트 • Feb 04
QTRX: New Leadership And Neurodegenerative Pipeline Will Balance Near Term Multiple Risks
Narrative Update on Quanterix Analysts have lifted their fair value estimate for Quanterix from US$6.00 to US$7.00, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that collectively support a higher long term price target range. What's in the News Quanterix submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for a multi analyte algorithmic blood test for Alzheimer’s disease, aimed at helping identify whether symptomatic patients are likely to have amyloid brain plaques using its Simoa technology and a panel of five biomarkers (p Tau 217, Ab42, Ab40, GFAP, NfL), supported by clinical evidence from more than 1,800 patients (Key Developments).내러티브 업데이트 • Jan 21
QTRX: Future Leadership And Biomarker Data Will Shape Balanced 2025 Outlook
Analysts have raised their price target on Quanterix to 7.33 from 6.00 previously, reflecting updated fair value estimates based on adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News The board has appointed Everett Cunningham as Chief Executive Officer, effective January 19, 2026.분석 기사 • Jan 10
Market Still Lacking Some Conviction On Quanterix Corporation (NASDAQ:QTRX)
Quanterix Corporation's ( NASDAQ:QTRX ) price-to-sales (or "P/S") ratio of 2.9x might make it look like a buy right now...내러티브 업데이트 • Jan 07
QTRX: Multiple Sclerosis Biomarker Validation Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Quanterix to US$8.00 from US$7.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News A study published in the journal Brain validates multiplexed Simoa assays for GFAP and NfL as a complementary approach for monitoring Multiple Sclerosis disease activity and progression.내러티브 업데이트 • Dec 23
QTRX: Elevated Multiple And Higher Discount Rate Will Pressure Prospects
Analysts have raised their price target on Quanterix by approximately 20 percent to around 6 dollars per share, citing a modestly higher fair value estimate, slightly stronger long term profitability assumptions, and a willingness to apply a richer future earnings multiple, despite trimming revenue growth expectations and using a higher discount rate. What's in the News Publication of a landmark Brain journal study validating Quanterix Simoa assays for GFAP and NfL as a complementary, two biomarker approach for comprehensive Multiple Sclerosis disease monitoring, covering both acute inflammatory activity and slow progression (Key Developments) Evidence that elevated serum GFAP levels are significantly associated with higher risk of progression independent of relapse activity, highlighting a major unmet therapeutic need in MS and expanding the clinical utility of Quanterix assays (Key Developments) Creation of large Simoa-based normative reference databases for GFAP and NfL, incorporating age, sex, and BMI, alongside a free online interpretive tool to support more precise, individualized MS risk assessment (Key Developments) Updated 2025 revenue guidance of 130 million to 135 million dollars, implying pro forma revenue of 165 million to 170 million dollars for the year if combined operations are assumed, with an expected GAAP gross margin of 45 percent to 47 percent (Key Developments) Valuation Changes Fair Value Estimate has risen modestly from approximately 5 dollars to 6.0 dollars per share.분석 기사 • Aug 28
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 29% Lower
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 29% after a relatively good period...내러티브 업데이트 • Aug 15
Biomarker Diagnostics And Proteomics Will Shape Future Markets
Analysts maintain a cautious stance on Quanterix due to near-term uncertainty, weak Q2 results, and biopharma sector headwinds, keeping the price target unchanged at $6.00. Analyst Commentary Downgrade reflects a lack of near-term visibility and absence of clear catalysts to drive the stock higher.분석 기사 • Aug 10
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
It's shaping up to be a tough period for Quanterix Corporation ( NASDAQ:QTRX ), which a week ago released some...분석 기사 • Jun 13
Even With A 33% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Those holding Quanterix Corporation ( NASDAQ:QTRX ) shares would be relieved that the share price has rebounded 33% in...분석 기사 • Apr 08
Market Cool On Quanterix Corporation's (NASDAQ:QTRX) Revenues Pushing Shares 30% Lower
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 30% in the last...
새로운 내러티브 • Mar 28
Simoa ONE Platform Will Revitalize Immunology And Oncology Markets
Strategic product expansion and key acquisitions could significantly enhance market reach and revenue potential in immunology and oncology markets.Seeking Alpha • Jan 11
Quanterix: Why Pursuing A Big Deal For Akoya?
Summary Quanterix's IPO in 2017 was highly speculative, with its Simoa technology promising ultra-sensitive diagnostics but accompanied by substantial operating losses and continued dilution. Despite revenue growth to $121 million in 2023, Quanterix still faces significant losses, and expects a $25-$30 million cash burn in 2024. Slower growth in 2024, compliance issues, and a controversial acquisition of Akoya Biosciences have pressured shares, raising concerns about combining two loss-making entities. The acquisition news led to a 20% share price drop, prompting a cautious outlook despite the potential synergies and growing revenue base. Read the full article on Seeking Alpha분석 기사 • Nov 07
Even With A 36% Surge, Cautious Investors Are Not Rewarding Quanterix Corporation's (NASDAQ:QTRX) Performance Completely
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a really impressive month, gaining 36% after a shaky period...분석 기사 • Oct 17
We're Hopeful That Quanterix (NASDAQ:QTRX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 26
Quanterix Corporation: Still Struggling To Gain Traction
Summary Today, we revisit Quanterix Corporation, which provides ultra-sensitive digital assay platforms for detecting protein biomarkers in healthcare. The company has a pristine balance sheet with some $300 million in net cash on it. Quanterix Corporation is also seeing steady revenue growth. Unfortunately, the firm is making little progress on the profitability front but is pushing further into early Alzheimer's detection. Will that enable Quanterix to “turn the corner”? An updated analysis follows in the paragraphs below. Read the full article on Seeking Alpha분석 기사 • Aug 15
Take Care Before Jumping Onto Quanterix Corporation (NASDAQ:QTRX) Even Though It's 26% Cheaper
To the annoyance of some shareholders, Quanterix Corporation ( NASDAQ:QTRX ) shares are down a considerable 26% in the...분석 기사 • Jun 27
Positive Sentiment Still Eludes Quanterix Corporation (NASDAQ:QTRX) Following 25% Share Price Slump
Unfortunately for some shareholders, the Quanterix Corporation ( NASDAQ:QTRX ) share price has dived 25% in the last...분석 기사 • Apr 14
Quanterix Corporation's (NASDAQ:QTRX) 31% Cheaper Price Remains In Tune With Revenues
Quanterix Corporation ( NASDAQ:QTRX ) shares have had a horrible month, losing 31% after a relatively good period...분석 기사 • Apr 05
Quanterix (NASDAQ:QTRX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...분석 기사 • Mar 03
Quanterix Corporation (NASDAQ:QTRX) Yearly Results: Here's What Analysts Are Forecasting For This Year
Investors in Quanterix Corporation ( NASDAQ:QTRX ) had a good week, as its shares rose 8.6% to close at US$27.00...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Quanterix가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 145 | -104 | 119 | 28 |
| 31 Dec 25 | 139 | -107 | 121 | 31 |
| 30 Sep 25 | 130 | -96 | 115 | 33 |
| 30 Jun 25 | 126 | -70 | 105 | 33 |
| 31 Mar 25 | 136 | -48 | 105 | 34 |
| 31 Dec 24 | 137 | -39 | 101 | 31 |
| 30 Sep 24 | 134 | -36 | 97 | 30 |
| 30 Jun 24 | 129 | -34 | 97 | 30 |
| 31 Mar 24 | 126 | -32 | 94 | 28 |
| 31 Dec 23 | 122 | -28 | 89 | 26 |
| 30 Sep 23 | 117 | -41 | 87 | 25 |
| 30 Jun 23 | 112 | -70 | 83 | 24 |
| 31 Mar 23 | 104 | -89 | 88 | 25 |
| 31 Dec 22 | 106 | -100 | 92 | 27 |
| 30 Sep 22 | 110 | -98 | 102 | 28 |
| 30 Jun 22 | 111 | -79 | 105 | 28 |
| 31 Mar 22 | 113 | -66 | 99 | 28 |
| 31 Dec 21 | 111 | -56 | 93 | 28 |
| 30 Sep 21 | 106 | -47 | 83 | 26 |
| 30 Jun 21 | 110 | -30 | 72 | 25 |
| 31 Mar 21 | 98 | -30 | 65 | 23 |
| 31 Dec 20 | 86 | -32 | 60 | 20 |
| 30 Sep 20 | 76 | -33 | 55 | 18 |
| 30 Jun 20 | 60 | -45 | 54 | 17 |
| 31 Mar 20 | 60 | -43 | 53 | 17 |
| 31 Dec 19 | 57 | -41 | 50 | 16 |
| 30 Sep 19 | 52 | -39 | 47 | 16 |
| 30 Jun 19 | 47 | -37 | 43 | 16 |
| 31 Mar 19 | 42 | -34 | 38 | 16 |
| 31 Dec 18 | 38 | -32 | 34 | 16 |
| 30 Sep 18 | 33 | -30 | 29 | 16 |
| 30 Jun 18 | 28 | -30 | 25 | 16 |
| 31 Mar 18 | 25 | -31 | 22 | 16 |
| 31 Dec 17 | 23 | -31 | 20 | 16 |
| 30 Sep 17 | 23 | -31 | 17 | 19 |
| 30 Jun 17 | 21 | -30 | 16 | 18 |
| 31 Mar 17 | 19 | -30 | 14 | 18 |
| 31 Dec 16 | 18 | -28 | 12 | 17 |
| 31 Dec 15 | 12 | -20 | 10 | 10 |
양질의 수익: QTRX 은(는) 현재 수익성이 없습니다.
이익 마진 증가: QTRX는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: QTRX은 수익성이 없으며 지난 5년 동안 손실이 연평균 8.6% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 QTRX의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: QTRX은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(3.8%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: QTRX는 현재 수익성이 없으므로 자본 수익률이 음수(-36.93%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/21 05:37 |
| 종가 | 2026/05/21 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Quanterix Corporation는 7명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |
| Matthew Sykes | Goldman Sachs |